Changes to the prescribing recommendation for therapeutic drug monitoring of Rapamune® (sirolimus)

Wyeth would like to inform healthcare professionals that switching between platforms for therapeutic drug monitoring of sirolimus, whether between immunoassay platforms or between immunoassay and HPLC, can produce differing results that may be clinically significant. Hence, if different assays are used in monitoring a single patient without the knowledge of the prescriber, the dose of Rapamune might be adjusted improperly with potential consequences, such as allograft rejection if drug exposure is too low or toxic side effects if exposure is too high. Wyeth is working with HSA to update the prescribing recommendation for therapeutic drug monitoring of Rapamune ® (sirolimus), based on the above findings. Wyeth is also advising all healthcare professionals involved in the management of patients taking Rapamune to determine the type of assay used in their laboratory(ies) and to note any changes to the assay and corresponding reference range used.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.